Table 3.

Major GLE/PIB clinical trials SVR results by category

Study	Arm	SVR by ITT (%)
(a) Dosing and RBV use
SURVEYOR-I, part 1	GLE 200 mg/PIB 40 mg	97
SURVEYOR-I, part 1	GLE 200 mg/PIB 120 mg	100
SURVEYOR-II, part 1	GLE 300 mg/PIB 120 mg	97
SURVEYOR-II, part 1	GLE 200 mg/PIB 120 mg	93
SURVEYOR-II, part 1	GLE 200 mg/PIB 120 mg + RBV	97
SURVEYOR-II, part 1	GLE 200 mg/PIB 40 mg	90
SURVEYOR-II, part 1	GLE 300 mg/PIB 120 mg	96
SURVEYOR-II, part 1	GLE 200 mg/PIB 120 mg	100
SURVEYOR-II, part 1	GLE 200 mg/PIB 120 mg + RBV	100
(b) Duration of therapy
SURVEYOR-I, part 2	8 weeks of GLE/PIB	97
SURVEYOR-I, part 2	12 weeks of GLE/PIB	100
SURVEYOR-II, part 2	8 weeks of GLE/PIB	98
SURVEYOR-II, part 2	8 weeks of GLE/PIB	97
SURVEYOR-II, part 2	12 weeks of GLE/PIB	92
SURVEYOR-II, part 4	8 weeks of GLE/PIB	97
ENDURANCE-I	8 weeks of GLE/PIB	99
ENDURANCE-I	12 weeks of GLE/PIB	100
ENDURANCE-III	12 weeks of GLE/PIB	95
ENDURANCE-III	8 weeks of GLE/PIB	95
EXPEDITION-II	8 weeks of GLE/PIB	99
(c) HIV co-infection
ENDURANCE-I	No cirrhosis	100
EXPEDITION-II	No cirrhosis	99
EXPEDITION-II	Compensated cirrhosis	88
(d) Cirrhosis
EXPEDITION-I	GT 1, 2, 4, 5, 6	99
EXPEDITION-II	GT 1, 2, 3, 4, 6	88
SURVEYOR-I and II, part 2	GT 1	96
SURVEYOR-I and II, part 2	GT 3 without RBV	96
SURVEYOR-I and II, part 2	GT 3 with RBV	100
SURVEYOR-II, part 3	GT 3, treatment naïve	98
SURVEYOR-II, part 3	GT 3, treatment experience	96
(e) Renal disease
EXPEDITION-IV	GT 1, 2, 3, 4, 5, 6	98
CERTAIN-I	GT 1, 2	100
(f) Organ transplantation
MAGELLAN-II	GT 1, 2, 3, 4, 6	98
(g) DAA failure
MAGELLAN-I, part 1	GLE/PIB with RBV	95
MAGELLAN-I, part 1	GLE/PIB without RBV	86
MAGELLAN-I, part 2	No cirrhosis	89
MAGELLAN-I, part 2	Compensated cirrhosis	91
CERTAIN-I	N/A	94

SVR sustained virologic response, ITT intention-to-treat, GLE glecaprevir, PIB pibrentasvir, GT genotype, RBV ribavirin, DAA direct-acting antiviral